NCT02606461 2023-01-23
SEAL
Karyopharm Therapeutics Inc
Phase 2/3 Completed
Clinical Trials
4 trialsNCT02301897 2019-06-19
A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT00785356 2014-08-21
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00454181 2011-09-16
Treatment of Oral Warts in HIV+ Patients
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Phase 2 Completed